Culture Development Featured Articles

  1. Challenges In Generating And Optimizing A 3D Cell Culture Model 3/20/2014

    Growing cells in a 3D culture is more preferable than a 2D culture on a plate or a support matrix because 3D culture allow the cells to grow with better cell-to-cell interaction and develop into a microtissue structure, which almost resembles the natural cellular environment.

  2. Rentschler To Hold 3rd Industrial Cell Culture Tech Conference 3/18/2014

    Rentschler Biotechnologie GmbH announced that it will hold the third Industrial Cell Culture Technology Conference this June in Laupheim, Germany.

  3. 3rd Industrial Cell Culture Technology Conference Announced By Rentschler 3/17/2014

    Rentschler is pleased to announce the Laupheimer Zelltage: a conference to take place in Laupheim, Germany on June 2nd and 3rd, Germany hopes to offer a platform for sharing ideas, knowledge and expertise in the world of cell culture technology.

  4. Hamilton Company Acquires Fogale's Biomass Measurement Business 12/9/2013

    Hamilton concludes agreement to acquire the biotech sensors business of the French company Fogale Nanotech.

  5. Noble Life Sciences Receives Grant To Develop Assays for Anti-Mestatic Drug Development 12/5/2013

    Noble Life Sciences (Gaithersburg, MD) announced today that the company has been awarded a Technology Commercialization Fund (TCF) grant of $100,000 from the Maryland Technology Development Corporation (TEDCO). The grant will be used to develop assays to determine the effect of cancer treatments on metastatic cells derived directly from patients. Metastasis-initiating tumor cells isolated from the blood of cancer patients will be used to assay the activity of drugs both in culture and in novel metastatic mouse models developed using these invasive circulating tumor cells (CTCs).

  6. Acquisition Expands Phase I Capabilities 12/3/2013

    Clinical research firm PRA has announced it will be acquiring privately-held specialty research firm CRI Lifetree. CRI’s focus has been on early stage patient population studies with a focus in Human Abuse Liability (HAL), addiction, pain, psychiatry, neurology, pediatric and infectious disease services.

    With three Clinical Pharmacology Centers and over 200 beds, combined with over 20 years of clinical experience, CRI is one of the largest providers of patient population Phase I and confined Phase II-III services in the United States. 

  7. New Application Of TAP's ambr Microscale Bioreactor As Perfusion Mimic 10/15/2013

    TAP Biosystems, a leading supplier of innovative cell culture and consumables for life science, recently announced a new application of its ambr micro bioreactor system as a perfusion mimic, enabling scientists to rapidly and easily develop large scale perfusion culture processes of unstable, low producing or minimally expressing proteins or antibodies.

  8. New Microplate Hotel For TAP's CompacT SelecT Extends Screening System Support 10/3/2013

    TAP Biosystems, a leading supplier of innovative cell culture systems and consumables for life science applications, recently introduced a new microplate hotel for use with its CompacT SelecT automated cell culture system. 

  9. Next Generation Single-Use Bioreactor Improves Cell Culture Performance 9/18/2013

    The next-generation HyPerforma Single-Use Bioreactor has been redesigned to provide improved ergonomics while retaining traditional stainless steel bioreactor design principles to enhance cell culture performance.

  10. Thermo Fisher Scientific Opens Its First Dry Powder Media Facility In APAC Region To Support Growing Biopharmaceutical Market 8/16/2013

    Thermo Fisher Scientific Inc., the world leader in serving science, today announced it is expanding its global cell culture and bioprocessing capabilities by opening a new manufacturing plant in Singapore to produce dry powder media (DPM), a crucial cell culture raw material used to manufacture biologics, including vaccines, anticancer therapeutics, and others. The facility is the first-ever cell culture DPM production site in Singapore and is designed to address the increased global requirements from biopharmaceutical companies to mitigate critical raw material supply risks.